[
  {
    "title": "迈威生物(688062.SH)：9MW3011注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2023/01/03173837255755.shtml",
    "datetime": "2023-01-03 17:38:33",
    "code": "688062"
  },
  {
    "title": "迈威生物：9MW3011注射液获药物临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2023/01/03172337255685.shtml",
    "datetime": "2023-01-03 17:23:18",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：与君实生物合作开发的阿达木单抗注射液增加适应症补充申请获得批准",
    "href": "http://stock.jrj.com.cn/2022/11/21163637154394.shtml",
    "datetime": "2022-11-21 16:36:44",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：9MW3011的新药临床试验申请获得FDA批准通知书",
    "href": "http://stock.jrj.com.cn/2022/11/20155137152385.shtml",
    "datetime": "2022-11-20 15:51:38",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：第三季度净亏损2.69亿元",
    "href": "http://stock.jrj.com.cn/2022/10/25173137082157.shtml",
    "datetime": "2022-10-25 17:31:53",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：9MW3011注射液用于β-地中海贫血、真性红细胞增多症的临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/10/19155137066953.shtml",
    "datetime": "2022-10-19 15:51:35",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：上半年净亏损4.23亿元",
    "href": "http://stock.jrj.com.cn/2022/08/30160836952731.shtml",
    "datetime": "2022-08-30 16:08:48",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：6MW3511注射液用于治疗晚期实体瘤获批临床",
    "href": "http://stock.jrj.com.cn/2022/08/23162236926363.shtml",
    "datetime": "2022-08-23 16:22:57",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：阿达木单抗注射液增加适应症补充申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/08/17175336908724.shtml",
    "datetime": "2022-08-17 17:53:08",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：9MW2821的新药临床试验申请正式获得FDA批准",
    "href": "http://stock.jrj.com.cn/2022/07/29162036853928.shtml",
    "datetime": "2022-07-29 16:20:24",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：565.6607万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2022/07/08165536794840.shtml",
    "datetime": "2022-07-08 16:55:49",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)及子公司近日收到增值税留抵退税1.32亿元",
    "href": "http://stock.jrj.com.cn/2022/06/21184836747222.shtml",
    "datetime": "2022-06-21 18:48:37",
    "code": "688062"
  },
  {
    "title": "迈威生物：6MW3511注射液获得药物临床试验申请受理通知书",
    "href": "http://stock.jrj.com.cn/2022/06/17114136737322.shtml",
    "datetime": "2022-06-17 11:41:05",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：6MW3511注射液的临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/06/16154936734584.shtml",
    "datetime": "2022-06-16 15:49:02",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：拟向泰康生物增资3.95亿元",
    "href": "http://stock.jrj.com.cn/2022/06/07191036710114.shtml",
    "datetime": "2022-06-07 19:10:13",
    "code": "688062"
  },
  {
    "title": "迈威生物：拟对全资子公司泰康生物增资3.95亿元",
    "href": "http://stock.jrj.com.cn/2022/06/07190536710074.shtml",
    "datetime": "2022-06-07 19:05:25",
    "code": "688062"
  },
  {
    "title": "迈威生物披露2022年一季报 实现营收406.80万元",
    "href": "http://stock.jrj.com.cn/2022/05/05090436565968.shtml",
    "datetime": "2022-05-05 09:04:55",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：一季度净亏损2.20亿元",
    "href": "http://stock.jrj.com.cn/2022/04/29205136507433.shtml",
    "datetime": "2022-04-29 20:51:26",
    "code": "688062"
  },
  {
    "title": "迈威生物2021年亏损7.7亿同比亏损增加 总经理刘大涛薪酬130.31万",
    "href": "http://stock.jrj.com.cn/2022/04/21185236420657.shtml",
    "datetime": "2022-04-21 18:52:12",
    "code": "688062"
  },
  {
    "title": "迈威生物2021年净亏损7.70亿元，亏损同比增长19.77%",
    "href": "http://stock.jrj.com.cn/2022/04/21090836416143.shtml",
    "datetime": "2022-04-21 09:08:46",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)2021年度净亏损7.7亿元",
    "href": "http://stock.jrj.com.cn/2022/04/20194336412128.shtml",
    "datetime": "2022-04-20 19:43:22",
    "code": "688062"
  },
  {
    "title": "A股异动 | 迈威生物(688062.SH)涨超6% 合作开发药品获药监局审批完毕",
    "href": "http://stock.jrj.com.cn/2022/03/03101034515082.shtml",
    "datetime": "2022-03-03 10:10:09",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：阿达木单抗注射液上市申请已处于“审批完毕-待制证”阶段",
    "href": "http://stock.jrj.com.cn/2022/03/02164034512432.shtml",
    "datetime": "2022-03-02 16:40:11",
    "code": "688062"
  },
  {
    "title": "迈威生物2021年亏损7.72亿同比亏损增加 销售费用增长较多",
    "href": "http://stock.jrj.com.cn/2022/02/24201334453215.shtml",
    "datetime": "2022-02-24 20:13:04",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：实控人、控股股东方面、董事、高管等延长股份锁定期",
    "href": "http://stock.jrj.com.cn/2022/02/21171534422886.shtml",
    "datetime": "2022-02-21 17:15:57",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：用于治疗晚期恶性肿瘤的注射用8MW2311的临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/02/14161034344706.shtml",
    "datetime": "2022-02-14 16:10:48",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：拟使用最高不超20亿元暂时闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/02/08183334308382.shtml",
    "datetime": "2022-02-08 18:33:45",
    "code": "688062"
  },
  {
    "title": "迈威生物2021年预计亏损6.66亿-7.82亿同比亏损增加 研发费用金额较高",
    "href": "http://stock.jrj.com.cn/2022/01/26051234217154.shtml",
    "datetime": "2022-01-26 05:12:09",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：预计2021年度净亏损6.66亿元-7.82亿元",
    "href": "http://stock.jrj.com.cn/2022/01/25181334213188.shtml",
    "datetime": "2022-01-25 18:13:44",
    "code": "688062"
  },
  {
    "title": "科创板新股迈威生物破发，跌超20%",
    "href": "http://stock.jrj.com.cn/2022/01/18093834168221.shtml",
    "datetime": "2022-01-18 09:38:59",
    "code": "688062"
  },
  {
    "title": "迈威生物、沪江材料和益客食品今日上市",
    "href": "http://stock.jrj.com.cn/ipo/2022/01/18082234167871.shtml",
    "datetime": "2022-01-18 08:22:35",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)披露中签结果：中签号码共有5.288万个",
    "href": "http://stock.jrj.com.cn/2022/01/05191634125908.shtml",
    "datetime": "2022-01-05 19:16:07",
    "code": "688062"
  },
  {
    "title": "【兑奖啦】科创板翱捷科技、迈威生物网上申购中签号出炉",
    "href": "http://stock.jrj.com.cn/ipo/2022/01/05191534125889.shtml",
    "datetime": "2022-01-05 19:15:49",
    "code": "688062"
  },
  {
    "title": "迈威生物(688062.SH)：IPO定价为34.80元/股 2022年1月4日申购",
    "href": "http://stock.jrj.com.cn/2021/12/30211534088425.shtml",
    "datetime": "2021-12-30 21:15:07",
    "code": "688062"
  },
  {
    "title": "迈威生物IPO：至今未盈利 四处融资还关联拆借 多项经营指标“恶化”",
    "href": "http://stock.jrj.com.cn/2021/12/22134034047141.shtml",
    "datetime": "2021-12-22 13:40:00",
    "code": "688062"
  },
  {
    "title": "迈威生物过会：今年IPO过关第289家 海通证券过19单",
    "href": "http://stock.jrj.com.cn/2021/09/06110933391257.shtml",
    "datetime": "2021-09-06 11:09:00",
    "code": "688062"
  },
  {
    "title": "一过一失败！天地环保冲刺科创板IPO被否，迈威生物成功闯关",
    "href": "http://stock.jrj.com.cn/2021/09/06094833390872.shtml",
    "datetime": "2021-09-06 09:48:07",
    "code": "688062"
  },
  {
    "title": "科创板上市委：迈威生物首发过会 天地环保遭否",
    "href": "http://stock.jrj.com.cn/2021/09/03181433381183.shtml",
    "datetime": "2021-09-03 18:14:33",
    "code": "688062"
  },
  {
    "title": "两轮问询回复后迎上会，迈威生物、天地环保9月3日接受科创板IPO审核",
    "href": "http://stock.jrj.com.cn/2021/08/30141133351852.shtml",
    "datetime": "2021-08-30 14:11:39",
    "code": "688062"
  },
  {
    "title": "迈威生物、天地环保将于9月3日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2021/08/27175733334408.shtml",
    "datetime": "2021-08-27 17:57:00",
    "code": "688062"
  },
  {
    "title": "相关市场空间受到限制？迈威生物二答科创板IPO问询",
    "href": "http://stock.jrj.com.cn/2021/08/23093633300897.shtml",
    "datetime": "2021-08-23 09:36:21",
    "code": "688062"
  },
  {
    "title": "新进展！迈威生物科创板IPO获问询",
    "href": "http://stock.jrj.com.cn/2021/04/19092332399074.shtml",
    "datetime": "2021-04-19 09:23:18",
    "code": "688062"
  },
  {
    "title": "历经三个月中止审核情形消除 迈威生物科创板IPO恢复审核",
    "href": "http://stock.jrj.com.cn/2021/04/01173832263882.shtml",
    "datetime": "2021-04-01 17:38:37",
    "code": "688062"
  }
]